VolitionRx partners with Sysmex to optimize Nu.Q NETs H3.1 assay on Sysmex platform

VolitionRX Ltd

VolitionRX Ltd

VNRX

0.00
  • VolitionRx entered a collaboration with Sysmex to optimize its Nu.Q NETs H3.1 assay on the Sysmex platform.
  • Partnership supports VolitionRx’s strategy to out-license the Nu.Q NETs test to global diagnostics groups using their installed analyzer base.
  • Work targets diseases linked to NETosis, including sepsis, positioning the assay for diagnostic use and low-cost patient monitoring.
  • VolitionRx pegged the Nu.Q NETs assay total addressable market at USD 3.8 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606170815PR_NEWS_USPR_____LN86013) on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.